IMMUNOREGULATION PROCESSES MEDIATED BY PROGRAMMED DEATH-LIGAND 1 (PD-L1)

E. Pignat1, A. Picciotta1, G. Bertani1, R. Di T인1, L. Bertoni1, S. Croc2, M. Bonacini2, P. Azzoni1, A. de Po1, C. Salvarni1, G. Carnevale1.1: University of Modena and Reggio Emilia, Department of Surgery, Medicine Dentistry and Morphological Sciences with Interest in Transplant, Modena, Italy; 2: Azienda Unità Sanitaria Locale di Reggio Emilia-IRCCS, Clinical Immunology, Allergy and Advanced Biotechnology Unit, Reggio Emilia, Italy; 3: Azienda Ospedaliero-Universitaria Policlinico di Modena, Rheumatology Unit, Modena, Italy

Background: Stem cells isolated from dental pulp (DPSCs) are characterized by a high rate of proliferation, low immunogenicity and a high ability to differentiate in different lineages (i.e. osteogenic, chondrogenic, adipogenic, myogenic and neural commitment). Their multipotency can be attributed to the peculiar embryological origin from the neural crest. DPSCs represent a promising stem cell resource since they hold a low ethical impact and can be easily isolated through routine dental procedures. These cells own immuno-modulatory properties, exerted through the activation of different mechanisms, including the Fas / FasL pathway, as well as through the release of soluble factors. Currently, other molecular mechanisms are under consideration such as PD-1 / PD-L1 pathway of cell co-culture.

Objectives: The aim of this research was to investigate whether the stimulation of PD-L1 in DPSCs can affect the immunomodulatory effects of these stem cells on peripheral blood mononuclear cells (PBMCs). Furthermore, the expression of PD-L1 was also assayed after the induction of osteogenic differentiation of DPSCs in order to evaluate a possible application of DPSCs in autoimmune inflammatory osteo-er erosive diseases.

Methods: Immuno-selection was performed on DPSCs isolated from waste material, against the stemness markers c-KIT and STRO-1, to obtain a pure stem cell population. Then, STRO-1+c-KIT+ DPSCs, were co-cultured either directly and indirectly with peripheral blood mononuclear cells (PBMCs) from healthy donors, previously activated by anti-CD3 and anti-CD28 antibodies. Co-cultures of PBMCs with amniotic fluid stem cells (AFSCs) and bone marrow mesenchymal stem cells (BM-MSCs) were also set up. The expression of PD-1 in PBMCs as well as of PD-L1 in DPSCs, AFSCs, BM-MSCs and PBMCs, was evaluated by Western Blot (WB) and immunofluorescence (IF) analyses, before and after osteogenic differentiation. Osteogenic differentiation of DPSCs, after 30 days of induction, was verified by IF and WB, of osteopontin, osteocalcin and RUNX2 markers. Interleukin-2 (IL-2) expression levels in PBMCs were analyzed by Real-Time PCR analysis.

Results: Our data highlight that, after direct and indirect co-culture with activated PBMCs, PD-L1 expression was up-regulated not only in DPSCs, but also in BM-MSCs and AFSCs (Figure 1), thus suggesting that 1) this is a common ability of mesenchymal stem cells and 2) this event can be also mediated by soluble factors release. Moreover, when evaluating the effects of DPSCs co-culture on PBMCs an increased expression of cleaved caspase 3 was observed, together with a decreased expression of IL-2 - a growth factor essential for the proliferation and survival of T cells (Figure 2). These findings showed how DPSCs can modulate the immune system by PD-L1 up-regulation. On the other hand, it is noteworthy that, after reaching osteogenic commitment, DPSCs down-regulated the expression of PD-L1, allowing to hypothesize that PD-L1 expression is strictly related to the maintenance of stemness.

Conclusions: Our results suggest that expression of PD-L1 in DPSCs is involved in the modulation of immune response and pave the way for further investigations on the role of PD-1/PD-L1 pathway in controlling inflammation and immune response when applied to the treatment of autoimmune inflammatory diseases.

References:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.3696

AB0040

IMPAIRED REGULATORY T CELL FUNCTIONS IN PATIENTS WITH PSORIASIS ARTHRITIS ELIGIBLE TO SWITCH TO ANTI-IL-17 TREATMENT

T. Christoforou1, G. Almanzar1, F. Brauneiser1, N. Buschmann1, M. Feuchtenberger2, M. Schmalzing2, H. P. Tony3, M. Goebeler3, M. Prelog1.1: University of Wuerzburg, University Children's Hospital, Pediatric Rheumatology/Special Immunology, Wuerzburg, Germany; 2: Department of Medicine II, Division of Rheumatology and Clinical Immunology, Albotting-Burghausen, Germany; 3: University Hospital Wuerzburg, Department of Medicine II, Rheumatology and Clinical Immunology, Wuerzburg, Germany; 4: University Hospital Wuerzburg, Department of Dermatology, Wuerzburg, Germany

Background: A dysbalance between Th17 and regulatory T cells (Treg) has been suggested for several T cell-mediated autoimmune disorders. Inhibitors of IL-17 are successfully used for treatment of psoriasis arthritis (PsA). However, so far reconstitution of Treg functions has not been studied in detail in PsA eligible for switching to anti-IL-17 treatment.

Objectives: The project aims to analyze the reconstitution and maintenance of regulatory T cell (Treg) function after inhibition of inflammatory Th17-inducing pathways mediated by IL-1, IL-6, IL-17 and TNFalpha in a longitudinal manner.

Methods: Therefore, Treg derived from 12 PsA patients switching to Th17 inhibition and healthy controls were phenotypically characterized by flow cytometry.

Conclusions: Taken together, our findings suggest that the expression of PD-L1 in DPSCs is involved in the modulation of immune response and pave the way for further investigations on the role of PD-1/PD-L1 pathway in controlling inflammation and immune response when applied to the treatment of autoimmune inflammatory diseases.

References:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.3696
Function was investigated by analysis of suppressive activity of Treg on proliferation of autologous effector T cells in vitro utilizing suppression assays.

**Results:** First results at the time-point of switching to anti–IL-17 treatment demonstrated a PsA to be an IL-17-driven T cell-mediated autoimmune disorder, as proportions of T cells with Th17 phenotype were increased in PsA compared to controls (CCR6+IL-17+ 4.9% vs. 0.8% of CD4+ and FoxP3+ Treg cells (CD25brightFoxP3+ 0.2% vs. 0.4% of CD4+ were decreased. Higher proportions of FoxP3+ T cells expressing the Th17-characteristic chemokine receptor CCR6 were found in PsA (4.8% vs. 2.7% of CD4+), as well as higher proportions of pro-apoptotic CD95-expressing FoxP3+ T cells (9.8% vs. 2.8% of CD4+). Less suppression of autologous effector T cells co-cultured with CD25+ Treg cells was found in PsA compared to controls (22.2% vs. 28.3% reduction of proliferative activity), whereas CD25- helper T cells did not contribute to the suppression of effectors in PsA and only minimally in controls. Intracellular IL-10 production in Tregs, a key cytokine of Treg-associated regulation of inflammation, was similar between PsA and controls, although a trend to lower CTLA-4 expression involved in inhibition of co-stimulation was found in PsA.

**Conclusion:** The current results indicate a skewed T cell balance towards Th17 cells and Treg cells showing Th17-like features in samples of PsA unsuccessfully pre-treated with different biologics recommending them for a switch to a therapy with selective inhibition of IL-17. Longitudinal results regarding the reconstitution and maintenance of Treg function in those PsA patients have to be awaited.

**Disclosure of Interests:** Timoteo Christoforou: None declared, Giovanni Almanzar Grant/research support from: Pfizer, Franziska Braunese: None declared, Nils Buschmann: None declared, Martin Feuchtenberger Consultant of: Abbvie, BMS, Chugai, Sanofi, Speakers bureau: Abbvie, BMS, Celgene, Chugai, Jansen-Cilag, Lilly, Pfizer, Roche, Sanofi, UCB, Marc Schmalzing Consultant of: Paid consultant for: Hexal AG, Hans-Peter Tony Consultant of: AbbVie, Astra-Zeneca, BMS, Chugai, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, Matthies Goebeler: None declared, Martina Prelog Grant/research support from: Chugai, Sobi, Novartis, Pfizer, Baxter, Consultant of: GSK, Pfizer, Novartis, MSD, Baxter, Sobi, Johnson, Speakers bureau: GSK, Pfizer, Novartis, MSD, Baxter, Sobi, Johnson

**DOI:** 10.1136/annrheumdis-2020-eular.6389

---

**AB0042 Cytokine Network Elucidated by the Quantification of Multiple Cytokines in the Serum Sequentially Sampled from RA Patients Who were Treated with Biologic DMARDs**

K. Sato1, S. Mamada1, C. Hayashi1, T. Nagashima1, S. Minota1, 1. Jichi Medical University; Division of Rheumatology and Clinical Immunology, Tochigi, Japan

**Objectives:** Biologic disease modifying anti-rheumatic drugs (DMARDs) have demonstrated that proinflammatory cytokines such as interleukin (IL)-6 and tumor necrosis factor (TNF) play important roles in the pathogenesis of rheumatoid arthritis (RA). Other cytokines, such as type I interferons (IFNs), are also implicated in its pathogenesis (1). However, the complete picture of the cytokine network involved in RA remains to be elucidated.

**Methods:** To quantitatively measure cytokines in the serum of RA patients before and after treatment with various biologic DMARDs, we sought to determine the effects of drugs on (A) type I IFNs, (B) soluble IL-6 receptors, and (C) other cytokines.

**Results:** We enrolled 52 patients with RA who were treated with various biologic DMARDs (tocilizumab (TOC): 16, abatacept (ABT): 15, and TNF inhibitors (TNFi); 21). Serum samples were obtained (1) before, (2) approximately 4 weeks after (3) and approximately 12 weeks after the initiation of treatment. A suspension bead-array system was used for analysis: Bio-Plex Human Cytokine 17-plex Assays and Express Custom Panels (Bio-Rad Laboratories, Hercules, CA). ELISA included INF-α, INF-β, soluble IL-6 receptor (sIL6Rα), and gp130 were used.

**Conclusion:** (1) As expected, the disease activity score 28-joint count (DAS28) using the erythrocyte sedimentation rate (ESR) significantly decreased in all three groups (TOC, ABT, and TNFi) by 12 weeks. (2) INF-αβ was barely detected in the serum samples. INF-β seemed to increase slightly in the ABT group, but the increase was not statistically significant. (3) The levels of sIL6Rα did not change substantially. Those of gp130 decreased slightly but significantly in the TOC group by 12 weeks. (4) The levels of IL-6 decreased significantly in the ABT group by 12 weeks. Those in the TNFi group decreased significantly at 4 weeks but not 12 weeks (Fig. 1A). (5) The levels of IL-7 decreased significantly only in the TOC group (Fig. 1B). (6) The biologic DMARDS tested in this study did not significantly affect the serum levels of type I IFNs in this study. (2) The decrease in gp130 in the TOC group may imply that gp130 is induced by IL-6, although whether this level of decrease has physiological significance is open to question. (3) Serum IL-6 was significantly decreased in the TNFi group at 4 weeks but not 12 weeks. TNF has been reported to induce IL-6 (ref 2), but negative feedback loop(s) may be present. Such a feedback system might make the discontinuation of TNFi difficult, even if patients are in remission. (4) IL-7 may be a target of IL-6. A higher level of IL-7 has been reported to be present in the joints of RA patients compared with osteoarthrosis and it is a cytokine implicated in the differentiation of osteoclasts (ref 3). This may partly explain the effect of TOC on preventing bone erosion in RA.

**References:**


**DOI:** 10.1136/annrheumdis-2020-eular.3145